Frontiers in Genetics (May 2024)
A panel based on three-miRNAs as diagnostic biomarker for prostate cancer
- Siwei Chen,
- Siwei Chen,
- Chong Lu,
- Chong Lu,
- Shengjie Lin,
- Shengjie Lin,
- Chen Sun,
- Chen Sun,
- Zhenyu Wen,
- Zhenyu Wen,
- Zhenjian Ge,
- Zhenjian Ge,
- Wenkang Chen,
- Wenkang Chen,
- Yingqi Li,
- Yingqi Li,
- Pengwu Zhang,
- Pengwu Zhang,
- Yutong Wu,
- Yutong Wu,
- Wuping Wang,
- Wuping Wang,
- Huimei Zhou,
- Huimei Zhou,
- Xutai Li,
- Xutai Li,
- Yongqing Lai,
- Yongqing Lai,
- Yongqing Lai,
- Yongqing Lai,
- Hang Li,
- Hang Li
Affiliations
- Siwei Chen
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Siwei Chen
- Shenzhen University Health Science Center, Shenzhen, China
- Chong Lu
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Chong Lu
- The Fifth Clinical Medical College of Anhui Medical University, Hefei, China
- Shengjie Lin
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Shengjie Lin
- Shantou University Medical College, Shantou, China
- Chen Sun
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Chen Sun
- The Fifth Clinical Medical College of Anhui Medical University, Hefei, China
- Zhenyu Wen
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Zhenyu Wen
- Shantou University Medical College, Shantou, China
- Zhenjian Ge
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Zhenjian Ge
- Shantou University Medical College, Shantou, China
- Wenkang Chen
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Wenkang Chen
- Shantou University Medical College, Shantou, China
- Yingqi Li
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Yingqi Li
- Shenzhen University Health Science Center, Shenzhen, China
- Pengwu Zhang
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Pengwu Zhang
- Peking University Health Science Center, Beijing, China
- Yutong Wu
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Yutong Wu
- Shantou University Medical College, Shantou, China
- Wuping Wang
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Wuping Wang
- Shenzhen University Health Science Center, Shenzhen, China
- Huimei Zhou
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Huimei Zhou
- The Fifth Clinical Medical College of Anhui Medical University, Hefei, China
- Xutai Li
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Xutai Li
- The Fifth Clinical Medical College of Anhui Medical University, Hefei, China
- Yongqing Lai
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Yongqing Lai
- The Fifth Clinical Medical College of Anhui Medical University, Hefei, China
- Yongqing Lai
- Shantou University Medical College, Shantou, China
- Yongqing Lai
- Peking University Health Science Center, Beijing, China
- Hang Li
- Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
- Hang Li
- Shenzhen University Health Science Center, Shenzhen, China
- DOI
- https://doi.org/10.3389/fgene.2024.1371441
- Journal volume & issue
-
Vol. 15
Abstract
Background: Prostate cancer (PCa) is one of the most prevalent malignancies affecting the male life cycle. The incidence and mortality of prostate cancer are also increasing every year. Detection of MicroRNA expression in serum to diagnose prostate cancer and determine prognosis is a very promising non-invasive modality.Materials and method: A total of 224 study participants were included in our study, including 112 prostate cancer patients and 112 healthy adults. The experiment consisted of three main phases, namely, the screening phase, the testing phase, and the validation phase. The expression levels of serum miRNAs in patients and healthy adults were detected using quantitative reverse transcription-polymerase chain reaction. Receiver operating characteristic (ROC) curves and the area under the curve (AUC) were used to evaluate the diagnostic ability, specificity, and sensitivity of the candidate miRNAs.Result: Eventually, three miRNAs most relevant to prostate cancer diagnosis were selected, namely, miR-106b-5p, miR-129-1-3p and miR-381-3p. We used these three miRNAs to construct a diagnostic panel with very high diagnostic potential for prostate cancer, which had an AUC of 0.912 [95% confidence interval (CI): 0.858 to 0.950; p < 0.001; sensitivity = 91.67%; specificity = 79.76%]. In addition, the three target genes (DTNA, GJB1, and TRPC4) we searched for are also expected to be used for prostate cancer diagnosis and treatment in the future.
Keywords
